Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 1-Year Low – Should You Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price reached a new 52-week low on Tuesday . The stock traded as low as $98.82 and last traded at $99.69, with a volume of 1639059 shares trading hands. The stock had previously closed at $103.03.

Analyst Ratings Changes

Several research analysts recently weighed in on SRPT shares. HC Wainwright reissued a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 27th. Royal Bank of Canada dropped their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Piper Sandler dropped their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft began coverage on Sarepta Therapeutics in a research report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 target price on the stock. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $170.41.

Sarepta Therapeutics Stock Performance

The firm has a 50 day moving average of $113.68 and a two-hundred day moving average of $120.98. The stock has a market cap of $9.67 billion, a P/E ratio of 79.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.70% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds have recently added to or reduced their stakes in SRPT. Capital International Investors raised its holdings in Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after acquiring an additional 2,437,855 shares in the last quarter. Norges Bank acquired a new position in Sarepta Therapeutics in the 4th quarter valued at approximately $126,315,000. Wellington Management Group LLP raised its holdings in Sarepta Therapeutics by 32.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company’s stock valued at $340,527,000 after acquiring an additional 665,087 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at approximately $79,425,000. Finally, Janus Henderson Group PLC raised its holdings in Sarepta Therapeutics by 14.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company’s stock valued at $544,408,000 after acquiring an additional 543,143 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.